Jean Gong, PhD

Adagio Therapeutics

Disclosure(s): Adagio Therapeutics: Employee, Stocks/Bonds

Poster(s):

• 226 - Higher Doses of Adintrevimab, an Extended Half-Life Monoclonal Antibody, for the Treatment and Prevention of COVID-19: Preliminary Results from a Phase 1 Single Ascending-Dose Study
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET

• 591 - Adintrevimab (ADI) Population Pharmacokinetics (PPK) in Phase 1 and Phase 2/3 COVID-19 Prevention and Treatment Study Participants
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET

• 1132 - Integrated Quantitative Systems Pharmacology (QSP) Characterizing Viral Dynamics After Intramuscular (IM) Adintrevimab (ADI) Administration in Participants with Mild to Moderate Coronavirus Disease (COVID-19)
  Friday, October 21, 2022

  12:15 PM – 1:30 PM US ET